Anti-Cyclic Citrullinated Peptide (Anti-CCP) and Anti-Mutated Citrullinated Vimentin (Anti-MCV) Relation with Extra-Articular Manifestations in Rheumatoid Arthritis

Table 3

Comparisons of characteristics between patients with ExRA and without extra-articular manifestations (RA w/out).

Clinical characteristics	RA w/out; 𝑛=130	ExRA; 𝑛=95	𝑃
Female, 𝑛 (%)	116 (89.2)	91 (95.8)	0.73
Age, years	50.75±10.92	54.82±10.62	0.006
Alcohol consumption, 𝑛 (%)	21 (16.2)	7 (7.4)	0.49
Smoke exposure, 𝑛 (%)	30 (23.1)	34 (35.8)	0.04
Disease duration, years	7.04±6.57	11.60±9.69	<0.001
DAS28	5.03±1.34	5.05±1.39	0.91
Tender joint count	4.28±4.91	7.40±7.18	0.004
Swollen joint count	6.42±6.89	7.47±8.08	0.43
VAS global	42.71±26.48	42.80±28.70	0.16
HAQ-Di score (units)	0.89±0.66	0.77±0.69	0.18
Global functioning status III-IV, 𝑛 (%)	23 (17.7)	20 (21)	0.53
Radiological Stage III or IV in hands, 𝑛 (%)	45 (34.7)	49 (51.6)	0.01
ESR, mm/h	29.40±11.56	28.97±12.40	0.79
CRP, mg/L	15.43±19.84	27.31±39.36	0.01
RF, IU/mL	119.07±252.69	119.16±220.03	0.99
Anti-CCP, IU/mL	67.99±74.14	78.62±104.86	0.40
Anti-MCV, IU/mL	155.60±179.03	158.58±190.44	0.91
MTX users, 𝑛 (%)	112 (86.2)	68 (71.6)	0.007
MTX dose, mean ± SD	7.33±4.14	6.37±5.16	0.12
Anti-TNF agents users, 𝑛 (%)	9 (6.9)	10 (10.5)	0.34

RA w/out: rheumatoid arthritis (RA) without extra-articular manifestations; ExRA: RA with extra-articular manifestations; DAS28: disease activity score; HAQ-Di: Health Assessment Questionnaire-Disability Index; ESR: erythrocyte sedimentation rate; RF: rheumatoid factor; CRP, C-Reactive Protein; anti-CCP: anti-cyclic citrullinated peptide antibodies; anti-MCV: anti-mutated citrullinated vimentin, DMARDs: disease-modifying antirheumatic drugs. Qualitative variables are expressed as frequencies (%); quantitative variables are expressed as mean and standard deviation. Comparisons between proportions were compared with Chi-square or Fisher exact test (when required). Comparisons between means were evaluated with Student’s 𝑡-test for independent samples.